Drug
Frovatriptan
Frovatriptan: highest development phase Phase 3, developed by Endo. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Endo
Trials
| Drug | Phase | Indication |
|---|---|---|
| Frovatriptan 2.5 mg NCT01035983 | Phase 3 | Migraine |
| frovatriptan NCT00700128 | Not Applicable | Migraines |
Latest
No recent events.
Follow Frovatriptan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.